Abstract
At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 310-345 |
| Number of pages | 36 |
| Journal | Cancer Cell |
| Volume | 39 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 8 2021 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- BRAF
- CD8 cytotoxic T lymphocytes
- CDK4/CDK6
- CGAS signaling
- DNA damage response
- EGFR
- KRAS
- T cells
- TGF-β
- immune checkpoint blockers
- immunogenic cell death
- Humans
- Antineoplastic Agents/immunology
- Disease Progression
- Animals
- Neoplasms/immunology
- Immunomodulation/immunology
Fingerprint
Dive into the research topics of 'Immunomodulation by targeted anticancer agents'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver